“BioChimpPharm” participated in the international workshop of the World Health Organization (WHO EURO) and the Global AMR R&D Hub: “Building the evidence base for broader use of bacteriophages for AMR from a One Health Perspective”

The speakers of “BioChimPharm” Rati Golijashvili (General Manager of JSC “BioChimPharm”) and Mariam Murtazashvili (Head of the quality control department of “BioChimPharm”) shared their experience to the workshop participants in the fight against AMR and production of GMP-compliant pharmaceuticals. The event was hosted by the National Center for Disease Control and Public Health (NCDC).

After the workshop, “BioChimPharm” hosted the World Health Organization (WHO EURO) team and phage specialists on a tour of the phage factory.

The Regional Export Director for Eastern Europe and Central Asia of the Department of Business and Trade of the UK Government, Sarah Chidgey, and the Deputy head of Mission, HM Consul at British Embassy, Claire Allbless, visited the BioChimPharm phage factory with embassy team.

Throughout the visit, guests engaged in an in-depth exploration of the production process and discussed potential partnership opportunities.

Mr.Alkis Drakinos, Regional Head of the Caucasus for the European Bank for Reconstruction and Development (EBRD) and EBRD team, conducted a visit to BioChimPharm’s historic phage factory.

Throughout the visit, EBRD team engaged in an in-depth exploration of the phage preparations production process and the operational procedures of the factory. Notably, the facility adheres to international good manufacturing practice (GMP) standards.

As a client and partner of the European Bank for Reconstruction and Development (EBRD) in the fight against antimicrobial resistance (AMR), BioChimPharm was included in the 2023 EBRD Sustainability Report. | With the support of the EBRD, as well as other local and international partners, " BioChimPharm " modernized the historical phage factory. With the compliance to standards recognized in the European Union, BioChimPharm received GMP certification.

As a result of the implementation of the 6.5 million euro project of renovation and modernization of the enterprise, the company took a leading position in the fight against the global antibiotic resistance crisis.

“Bacteriophages, also known as phages, are microorganisms, that specifically target bacteria. Phage therapy involves using phages to treat bacterial infections. In contrast to many antibiotics, phages target bacterial strains or species more narrowly, making phage therapy an attractive alternative for managing infections. Modernising BioChimPharm’s manufacturing plant in compliance with GMP will enable it to scale up production and potentially export phage products” – states the report.

The biopharmaceutical cluster of Georgia, with the support of the European Union and the United Nations Industrial Development Organization (UNIDO), held the international conference: "Biopharma 2023 Georgia" within the framework of the "EU innovative project for the competitiveness of the private sector in Georgia". The conference was held on November 17, at Sheraton Grand Tbilisi Metekhi Palace, where both local and international representatives working in the field of biopharmaceutical and biotechnology gathered.

The conference was opened and the invited guests were addressed by the following representatives:
• Rati Gholijashvili, Chairman of the Board of the Georgian Biopharmaceutical Cluster;
• Mindi Bozhkova, attaché of the EU representation in Georgia;
• Giorgi Andghuladze, national coordinator of UNIDO projects;
• Avtandil Kasradze, Chairman of the Agency of Innovations and Technologies of Georgia;
• Levan Gogiberidze, President of the Association of Pharmacists of Georgia.

Event Moderator:
• President of the Regional Health Protection Association, Acad. Ph.D., Assoc. Professor, Tamta Ivanashvili

The following were presented with a report:
• Doctor of Pharmaceutical Sciences, Prof. Aleko Bakuridze
• M. Iashvili house Children's Central Hospital. Medical Director, MD, Prof. Ivane Chkhaidze
• National Center for Disease Control and Public Health, MD, Lille Malania
• Senior Adviser on Antimicrobial Resistance (AMR) Policy, Nobuko Ichikawa
• TSU professor, Tamaz Murtazashvili
• UNIDO GMP national expert, Ekaterine Koplatadze
• President of Makoto Investments, Brad Schmidt

The following participated in the panel discussions:
• Executive Director of the Association of Representatives of Pharmaceutical Companies, Irakli Margvelashvili
• Chairman of biopharmaceutical cluster, general manager of JSC Biochemfarm, Rati Gholijashvili
• Ilyauni Assoc. Professor, phage technology expert, Ekaterine Tevdoradze
• Eliava biopreparations, director, Vakhtang Favlenishvili
• c. Eliava International Phage Therapy Center, Director, Davit Sturua
• President of the Association of Pharmacists of Georgia, Levan Gogiberidze
• Kamelin, Tamaz Murtazashvili
• Neofarm, director, Lasha Bakuridze
• Tbilisi State Medical University, Koba Sivsivadze
• Officer, director, Marina Ramishvili
• Acad. Doctor, head of quality of JSC Biochempharma/qualified person, Imeda Rubashvili
• International GMP expert of UNIDO, Mrs. Susan Mann,
• Head of Quality Control Department of Biochemfarm, Medical Univ. Lecturer, Mariam Murtazashvili
• Head of quality engineering group, Nodar Labadze
• UNIDO cluster development agent, Ketevan Buachidze

🌟 Thanks to all speakers, moderators, participants and guests! Sincere thanks to everyone for their involvement and cooperation.

BioChimPharm, the founding member of the Georgian Bio Pharmaceutical cluster, has completed EUR 6 million modernization project at the historic phage manufacturing facility in Tbilisi, which dates back to 1934. BioChimPharm is now producing life-saving, phage-based novel antibiotics with European precision and quality.

„We would like to express our heartfelt appreciation to our dear local and international partners (European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank and GITA) without whom this project would not have been possible. To honor their contributions, we proudly introduce the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing Phage Technology.

In today’s focus, we highlight the European Union and the FAO Georgia! We extend our sincere gratitude to the Food and Agriculture Organization (FAO), the FAO Georgia team, and the FAO Programme Coordinator, Javier Sanz Alvarez, for their remarkable support, under ENPARD III of the European Union, in the fight against AMR and the development of Phage Technology.

Please join us in celebrating this achievement by viewing the photos from our prize-giving ceremony, which showcase the dedication of our partners. Together, we are making significant strides in combating AMR and propelling Phage Technology. “ – Rati Golijashvili, General Manager of JSC Biochimpharm.

BioChimPharm, the founding member of the Georgian Bio Pharmaceutical cluster, has completed EUR 6 million modernization project at the historic phage manufacturing facility in Tbilisi, which dates back to 1934. BioChimPharm is now producing life-saving, phage-based novel antibiotics with European precision and quality.

„We would like to express our heartfelt appreciation to our dear local and international partners (European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank and GITA) without whom this project would not have been possible. To honor their contributions, we proudly introduce the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing Phage Technology.

In today’s focus, we highlight the EBRD! We extend our sincere gratitude to the European Bank for Reconstruction and Development, the EBRD Georgia team, and EBRD Regional Director, Catarina Bjorlin Hansen, for their remarkable support in the fight against AMR and the development of Phage Technology.

Please join us in celebrating this achievement by viewing the photos from our prize-giving ceremony, which showcase the dedication of our partners. Together, we are making significant strides in combating AMR and propelling Phage Technology. “ – Rati Golijashvili, General Manager of JSC Biochimpharm.

The Georgian pharmaceutical company "Neopharm" successfully passed the GDP (Good Distribution Practice) inspection and received the relevant standard certificate.

GDP is a globally recognized standard that helps pharmaceutical companies ensure the safe supply of medicines to the market.

A quality management system has been implemented in the "Neopharm" company, which ensures the supply of quality, effective and safe medicines at all stages of the distribution chain.

The pharmaceutical company "Neopharm" was founded in 1997 and has been part of the country's healthcare system for 25 years. The product portfolio consists of innovative, original prescription medicinal products, mostly made from herbal raw materials. Special technology ensures that the active pharmaceutical ingredient is obtained from plant raw materials in its natural state, which leads to the high efficiency of the final product and fewer side effects compared to synthetic substances.

Today, the company serially manufactures more than 100 products, including tinctures, extracts, syrups, herbal oils, capsules, tablets, ointments, eye drops, herbal substances, and cosmetics.